Fig. 5From: Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumorsErlotinib does not diminish T cell proliferation in vitro or in vivo. Quantification of erlotinib-treated (a) CD8 and (b) CD4 T cells isolated using magnetic beads from lungs and spleens of tumor bearing four CCSP-rtTA; TetO-EGFRL858R + T790M mice and labeled with CFSE. The proportion of dividing cells was assessed 120 h after 10 μm erlotinib or DMSO treatment based on CFSE dilution. (c) Experimental layout of control, non-tumor bearing CCSP-rtTA; TetO-EGFRL858R mice infected with LCMV for 8 days with intervening daily administration of erlotinib or vehicle for 5 days, (n = 3 mice per group). Splenic T cells were collected and analyzed by flow cytometry. (d) Representative FACS plot showing the percentage of CD44+ CD4+ or CD44+ CD8+ T cells and quantification of (e) CD44+ CD4+ or CD44+ CD8+ T cells. (f) Ki-67+ CD4+ or Ki-67+ CD8+ T cells from vehicle or erlotinib treated LCMV infected mice. Data are shown as mean ± SD and * is P < 0.05 in a student’s t-testBack to article page